Dragonfly Therapeutics is a clinical-stage biotech developing novel first-in-class therapeutics targeted at natural killer cells and other cells of the innate immune system. These therapies are designed to counterbalance immune suppressive factors present in the tumor microenvironment and mobilize anti-cancer immune responses. Our molecules are expected to be potent as single agents as well as in treatment combinations with existing cancer immunotherapies. Our scientific founders are major figures in cancer biology and immunology and have launched Dragonfly to harness the power of the immune system to provide breakthrough cancer treatments for patients. For more information, email info@dragonflytx.com.
Location: United States, Massachusetts, Waltham
Employees: 51-200
Founded date: 2015
Investors 1
| Date | Name | Website |
| - | Agent Capi... | agentcapit... |
Mentions in press and media 8
| Date | Title | Description |
| 05.08.2024 | Dragonfly Therapeutics Appoints Dr. Susan Altschuller as Chief Financial Officer | Dr. Altschuller brings over two decades of clinical and commercial biotechnology experience as the company grows its clinical pipeline to five autoimmune disease and oncology drug candidates. WALTHAM, Mass., Aug. 5, 2024 /PRNewswire/ -- Dra... |
| 13.07.2023 | Genedata Announces Partnership with Dragonfly Therapeutics to Support Novel Immune Engager R&D | We selected Genedata Biologics because of its unique workflow and registration engine that supports processes from candidate selection all the way through IND filings and commercialization. Ann Cheung, Ph.D., Head of Research at Dragonfly T... |
| 06.01.2023 | Dragonfly Therapeutics Announces Sixth Dragonfly TriNKET Opt-in by Bristol Myers Squibb | Since their original 2017 collaboration focusing on hematology malignancies, the companies have agreed to two additional collaborations which include oncology and neuroinflammation targets. Today's announcement marks the first TriNKET opt-i... |
| 12.01.2021 | Dragonfly Therapeutics Announces AbbVie Opt-In of TriNKET™ Immunotherapy Drug Candidate USA - English España - español France - Français Deutschland - Deutsch | |
| 01.12.2020 | Dragonfly Therapeutics Announces Merck Opt-In of TriNKET™ Immunotherapy Candidate for Patients with Solid Tumors USA - English España - español France - Français Deutschland - Deutsch | |
| 24.11.2020 | Dragonfly Therapeutics Expands Leadership Team with Chief Operating Officer and also Strengthens Scientific Advisory Board | |
| 20.03.2020 | Dragonfly Therapeutics Closes Funding Round | Dragonfly Therapeutics, Inc., a Waltham, MA-based clinical-stage biopharmaceutical company, raised a new funding round. The amount of the deal was not disclosed. Fidelity Management & Research Company has led a new round of investment, ... |
| 15.05.2017 | Dragonfly Therapeutics Closes New Funding Round | Dragonfly Therapeutics, Inc., a Cambridge, Mass.-based developer of drugs to stimulate immune responses against cancer, closed a new investment round of undisclosed amount. Backers included Celgene Switzerland, the Duke of Bedford, Disney f... |